Oxidative stress and cardiac hypertrophy: A review

Toxicology Mechanisms and Methods

Volumn 22, Issue 5, 2012, Pages 359-366

  Maulik, Subir Kumar ^a   Kumar, Santosh ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

antioxidants; NADPH oxidase; Reactive oxygen species

Indexed keywords

ANTIOXIDANT; CATALASE; DNA; ENZYME; FREE RADICAL; GLUTATHIONE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SUPEROXIDE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; XANTHINE OXIDASE;

ANTIOXIDANT ACTIVITY; CATALYSIS; CELL FUNCTION; DISEASE COURSE; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; GENETIC TRANSCRIPTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE WALL; HOMEOSTASIS; HUMAN; IMMUNITY; INTRACELLULAR SIGNALING; INTRACELLULAR SPACE; MACROMOLECULE; MITOCHONDRIAL MEMBRANE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UPREGULATION; VASCULAR FIBROSIS; WALL STRESS;

ANIMALS; ANTIOXIDANTS; CARDIOMEGALY; HUMANS; MITOCHONDRIA, HEART; MITOGEN-ACTIVATED PROTEIN KINASES; NADPH OXIDASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84860845011     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2012.666650     Document Type: Review

References (88)

1. Ago T, Kuroda J, Pain J, Fu C, Li H, Sadoshima J. 2010. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res 106:1253-1264.
2. Aikawa R, Nagai T, Tanaka M, Zou Y, Ishihara T, Takano H, Hasegawa H, Akazawa H, Mizukami M, Nagai R, Komuro I. 2001. Reactive oxygen species in mechanical stress-induced cardiac hypertrophy. Biochem Biophys Res Commun 289:901-907. (Pubitemid 34060090)
3. Akar FG, Aon MA, Tomaselli GF, O'Rourke B. 2005. The mitochondrial origin of postischemic arrhythmias. J Clin Invest 115:3527-3535. (Pubitemid 43121840)
4. Assem M, Teyssier JR, Benderitter M, Terrand J, Laubriet A, Javouhey A, David M, Rochette L. 1997. Pattern of superoxide dismutase enzymatic activity and RNA changes in rat heart ventricles after myocardial infarction. Am J Pathol 151:549-555. (Pubitemid 27330074)
5. Babior BM, Kipnes RS, Curnutte JT. 1973. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 52:741-744.
6. Backs J, Backs T, Neef S, Kreusser MM, Lehmann LH, Patrick DM, Grueter CE, Qi X, Richardson JA, Hill JA, Katus HA, Bassel- Duby R, Maier LS, Olson EN. 2009. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci USA 106:2342-2347.
7. Bagchi D, Sen CK, Ray SD, Das DK, Bagchi M, Preuss HG, Vinson JA. 2003. Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract. Mutat Res 523-524:87-97. (Pubitemid 36293235)
8. Bánfi B, Malgrange B, Knisz J, Steger K, Dubois-Dauphin M, Krause KH. 2004. NOX3, a superoxide-generating NADPH oxidase of the inner ear. J Biol Chem 279:46065-46072. (Pubitemid 39491600)
9. Bánfi B, Molnár G, Maturana A, Steger K, Hegedûs B, Demaurex N, Krause KH. 2001. A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes. J Biol Chem 276:37594-37601.
10. Barone FC, Campbell WG Jr, Nelson AH, Feuerstein GZ. 1998. Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. J Hypertens 16:871-884. (Pubitemid 28247971)
11. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, Molkentin JD. 2000. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19:6341-6350.
12. Bui AL, Horwich TB, Fonarow GC. 2011. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8:30-41.
13. Burton KP. 1988. Evidence of direct toxic effects of free radicals on the myocardium. Free Radic Biol Med 4:15-24. (Pubitemid 18037803)
14. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC, Shah AM. 2003. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 93:802-805.
15. Cai H. 2005. Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. Cardiovasc Res 68:26-36. (Pubitemid 41253553)
16. Cave A, Grieve D, Johar S, Zhang M, Shah AM. 2005. NADPH oxidasederived reactive oxygen species in cardiac pathophysiology. Philos Trans R Soc Lond, B, Biol Sci 360:2327-2334. (Pubitemid 46682152)
17. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM. 2006. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8:691-728. (Pubitemid 44043102)
18. Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal- Ginard B, Kajstura J, Leri A, Anversa P. 2001. Oxidative stressmediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 89:279-286. (Pubitemid 34132687)
19. Cheng G, Cao Z, Xu X, van Meir EG, Lambeth JD. 2001. Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. Gene 269:131-140. (Pubitemid 32488913)
20. Chess DJ, Xu W, Khairallah R, O'Shea KM, Kop WJ, Azimzadeh AM, Stanley WC. 2008. The antioxidant tempol attenuates pressure overload-induced cardiac hypertrophy and contractile dysfunction in mice fed a high-fructose diet. Am J Physiol Heart Circ Physiol 295:H2223-H2230.
21. Colan SD, Sanders SP, MacPherson D, Borow KM. 1985. Left ventricular diastolic function in elite athletes with physiologic cardiac hypertrophy. J Am Coll Cardiol 6:545-549. (Pubitemid 16219230)
22. Dai DF, Chen T, Szeto H, Nieves-Cintrón M, Kutyavin V, Santana LF, Rabinovitch PS. 2011. Mitochondrial targeted antioxidant Peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol 58:73-82.
23. Dai DF, Rabinovitch P. 2011. Mitochondrial oxidative stress mediates induction of autophagy and hypertrophy in angiotensin-II treated mouse hearts. Autophagy 7:917-918.
24. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, Manolio TA, Dries DL, Siscovick DS. 2004. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 43:2207-2215. (Pubitemid 38757586)
25. Dröge W. 2002. Free radicals in the physiological control of cell function. Physiol Rev 82:47-95. (Pubitemid 34654215)
26. Elahi MM, Naseem KM, Matata BM. 2007. Nitric oxide in blood. The nitrosative-oxidative disequilibrium hypothesis on the pathogenesis of cardiovascular disease. FEBS J 274:906-923. (Pubitemid 46204411)
27. Feuerstein GZ, Ruffolo RR Jr. 1995. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 16 Suppl F:38-42.
28. Forman HJ, Zhang H, Rinna A. 2009. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med 30:1-12.
29. Frey N, Katus HA, Olson EN, Hill JA. 2004. Hypertrophy of the heart: a new therapeutic target? Circulation 109:1580-1589. (Pubitemid 38451712)
30. Fridovich I. 1997. Superoxide anion radical (O2-.), superoxide dismutases, and related matters. J Biol Chem 272:18515-18517. (Pubitemid 27318184)
31. Geiszt M, Kopp JB, Várnai P, Leto TL. 2000. Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 97:8010-8014. (Pubitemid 30460764)
32. Giordano FJ. 2005. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115:500-508. (Pubitemid 40322219)
33. Gongora MC, Qin Z, Laude K, Kim HW, McCann L, Folz JR, Dikalov S, Fukai T, Harrison DG. 2006. Role of extracellular superoxide dismutase in hypertension. Hypertension 48:473-481. (Pubitemid 44253743)
34. Griendling KK, Sorescu D, Ushio-Fukai M. 2000. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86:494-501. (Pubitemid 30165039)
35. Grieve DJ, Byrne JA, Siva A, Layland J, Johar S, Cave AC, Shah AM. 2006. Involvement of the nicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload. J Am Coll Cardiol 47:817-826. (Pubitemid 43243107)
36. Gupta MK, Neelakantan TV, Sanghamitra M, Tyagi RK, Dinda A, Maulik S, Mukhopadhyay CK, Goswami SK. 2006. An assessment of the role of reactive oxygen species and redox signaling in norepinephrine-induced apoptosis and hypertrophy of H9c2 cardiac myoblasts. Antioxid Redox Signal 8:1081-1093.
37. Gupta S, Das B, Sen S. 2007. Cardiac hypertrophy: mechanisms and therapeutic opportunities. Antioxid Redox Signal 9:623-652. (Pubitemid 46799096)
38. Halliwell B and Gutteridge JMC. Free radicals in biology and medicine. London, Great Britain: Oxford university press. 1989.
39. Hao J, Kim CH, Ha TS, Ahn HY. 2007. Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Sci 8:121-129. (Pubitemid 46842638)
40. Hasegawa H, Takano H, Kohro T, Ueda K, Niitsuma Y, Aburatani H, Komuro I. 2006. Amelioration of hypertensive heart failure by amlodipine may occur via antioxidative effects. Hypertens Res 29:719-729. (Pubitemid 44605371)
41. Hikoso S, Yamaguchi O, Nakano Y, Takeda T, Omiya S, Mizote I, Taneike M, Oka T, Tamai T, Oyabu J, Uno Y, Matsumura Y, Nishida K, Suzuki K, Kogo M, Hori M, Otsu K. 2009. The I{kappa}B kinase {beta}/nuclear factor {kappa}B signaling pathway protects the heart from hemodynamic stress mediated by the regulation of manganese superoxide dismutase expression. Circ Res 105:70-79.
42. Hingtgen SD, Li Z, Kutschke W, Tian X, Sharma RV, Davisson RL . (2010). Superoxide Scavenging and AKT Inhibition in the Myocardium Ameliorate Pressure Overload-induced NF{kappa}B Activation and Cardiac Hypertrophy. Physiol Genomics 41:127-136.
43. Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H, Yamaguchi O, Mano T, Matsumura Y, Ueno H, Tada M, Hori M. 2002. Involvement of nuclear factor-?B and apoptosis signalregulating kinase 1 in G-protein-coupled receptor agonistinduced cardiomyocyte hypertrophy. Circulation 105:509-515. (Pubitemid 34141710)
44. Jaiswal A, Kumar S, Enjamoori R, Seth S, Dinda AK, Maulik SK. 2010. Peripheral benzodiazepine receptor ligand Ro5-4864 inhibits isoprenaline-induced cardiac hypertrophy in rats. Eur J Pharmacol 644:146-153.
45. Javadov S, Karmazyn M, Escobales N. 2009. Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J Pharmacol Exp Ther 330:670-678.
46. Kohler JJ, Cucoranu I, Fields E, Green E, He S, Hoying A, Russ R, Abuin A, Johnson D, Hosseini SH, Raper CM, Lewis W. 2009. Transgenic mitochondrial superoxide dismutase and mitochondrially targeted catalase prevent antiretroviral-induced oxidative stress and cardiomyopathy. Lab Invest 89:782-790.
47. Kumar S, Enjamoori R, Jaiswal A, Ray R, Seth S, Maulik SK. 2009. Catecholamine-induced myocardial fibrosis and oxidative stress is attenuated by Terminalia arjuna (Roxb.). J Pharm Pharmacol 61:1529-1536.
48. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J. 2010. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci USA 107:15565-15570.
49. Kwon SH, Pimentel DR, Remondino A, Sawyer DB, Colucci WS. 2003. H(2)O(2) regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. J Mol Cell Cardiol 35:615-621. (Pubitemid 36677445)
50. Laskowski A, Woodman OL, Cao AH, Drummond GR, Marshall T, Kaye DM, Ritchie RH. 2006. Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc Res 72:112-123. (Pubitemid 44310640)
51. Leung AW, Halestrap AP. 2008. Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim Biophys Acta 1777:946-952.
52. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM. 2002. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40:477-484.
53. Lyle AN, Griendling KK. 2006. Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology (Bethesda) 21:269-280. (Pubitemid 44156859)
54. MacCarthy PA, Grieve DJ, Li JM, Dunster C, Kelly FJ, Shah AM. 2001. Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase. Circulation 104:2967-2974. (Pubitemid 33139111)
55. McMullen JR, Jennings GL. 2007. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 34:255-262.
56. Nakagami H, Takemoto M, Liao JK. 2003. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 35:851-859. (Pubitemid 36773597)
57. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, Yamamoto M, Miyaji K, Saito H, Morita H, Emori T, Matsubara H, Toyokuni S, Ohe T. 2002. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 105:2867-2871. (Pubitemid 34666100)
58. Nauser T, Koppenol WH, Gebicki JM. 2005. The kinetics of oxidation of GSH by protein radicals. Biochem J 392:693-701. (Pubitemid 43022750)
59. Papparella I, Ceolotto G, Montemurro D, Antonello M, Garbisa S, Rossi G, Semplicini A. 2008. Green tea attenuates angiotensin II-induced cardiac hypertrophy in rats by modulating reactive oxygen species production and the Src/epidermal growth factor receptor/Akt signaling pathway. J Nutr 138:1596-1601.
60. Priyadarshi S, Valentine B, Han C, Fedorova OV, Bagrov AY, Liu J, Periyasamy SM, Kennedy D, Malhotra D, Xie Z, Shapiro JI. 2003. Effect of green tea extract on cardiac hypertrophy following 5/6 nephrectomy in the rat. Kidney Int 63:1785-1790. (Pubitemid 36513324)
61. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, Lin A. 2001. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci USA 98:6668-6673. (Pubitemid 32538274)
62. Ritchie RH, Quinn JM, Cao AH, Drummond GR, Kaye DM, Favaloro JM, Proietto J, Delbridge LM. 2007. The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4- deficient mouse in vivo. J Mol Cell Cardiol 42:1119-1128. (Pubitemid 46829196)
63. Rizzi E, Castro MM, Ceron CS, Neto-Neves EM, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF. (2011). Tempol inhibits TGF-β and MMPs upregulation and prevents cardiac hypertensive changes. Int J Cardiol. DOI:10.1016/j.ijcard.2011.08.060.
64. Sabri A, Byron KL, Samarel AM, Bell J, Lucchesi PA. 1998. Hydrogen peroxide activates mitogen-activated protein kinases and Na+-H+ exchange in neonatal rat cardiac myocytes. Circ Res 82:1053-1062. (Pubitemid 28249066)
65. Sabri A, Hughie HH, Lucchesi PA. 2003. Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid Redox Signal 5:731-740. (Pubitemid 37462056)
66. Schreck R, Albermann K, Baeuerle PA. 1992. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun 17:221-237. (Pubitemid 23207431)
67. Siwik DA, Colucci WS. 2004. Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev 9:43-51. (Pubitemid 38196076)
68. Suematsu N, Tsutsui H, Wen J, Kang D, Ikeuchi M, Ide T, Hayashidani S, Shiomi T, Kubota T, Hamasaki N, Takeshita A. 2003. αOxidative stress mediates tumor necrosis factor-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 107:1418-1423. (Pubitemid 36350742)
69. Suzuki YJ, Forman HJ, Sevanian A. 1997. Oxidants as stimulators of signal transduction. Free Radic Biol Med 22:269-285. (Pubitemid 26399334)
70. Tachibana H, Perrino C, Takaoka H, Davis RJ, Naga Prasad SV, Rockman HA. 2006. JNK1 is required to preserve cardiac function in the early response to pressure overload. Biochem Biophys Res Commun 343:1060-1066.
71. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, Lazzarino G, Paolocci N, Gabrielson KL, Wang Y, Kass DA. 2005. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 115:1221-1231. (Pubitemid 40629040)
72. Takimoto E, Kass DA. 2007. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49:241-248. (Pubitemid 46142995)
73. Tanaka K, Honda M, Takabatake T. 2001. Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. J Am Coll Cardiol 37:676-685.
74. Tardiff JC, Hewett TE, Factor SM, Vikstrom KL, Robbins J, Leinwand LA. 2000. Expression of the beta (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects. Am J Physiol Heart Circ Physiol 278:H412-H419. (Pubitemid 30131239)
75. Ushio-Fukai M. 2007. VEGF signaling through NADPH oxidasederived ROS. Antioxid Redox Signal 9:731-739. (Pubitemid 46799105)
76. Veenman L, Gavish M. 2006. The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development. Pharmacol Ther 110:503-524.
77. Watkins H, Ashrafian H, Redwood C. 2011. Inherited cardiomyopathies. N Engl J Med 364:1643-1656.
78. Wei S, Rothstein EC, Fliegel L, Dell'Italia LJ, Lucchesi PA. 2001. Differential MAP kinase activation and Na(+)/H(+) exchangerphosphorylation by H(2)O(2) in rat cardiac myocytes. Am J Physiol, Cell Physiol 281:C1542-C1550.
79. Xiao J, Liang D, Zhang H, Liu Y, Li F, Chen YH. 2010. 4'-Chlorodiazepam, a translocator protein (18 kDa) antagonist, improves cardiac functional recovery during postischemia reperfusion in rats. Exp Biol Med (Maywood) 235:478-486.
80. Xiao L, Pimentel DR, Wang J, Singh K, Colucci WS, Sawyer DB. 2002. αRole of reactive oxygen species and NAD(P)H oxidase in (1)-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol, Cell Physiol 282:C926-C934. (Pubitemid 34663155)
81. Xu X, Hu X, Lu Z, Zhang P, Zhao L, Wessale JL, Bache RJ, Chen Y. 2008. Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail 14:746-753.
82. Xu X, Zhao L, Hu X, Zhang P, Wessale J, Bache R, Chen Y. 2010. Delayed treatment effects of xanthine oxidase inhibition on systolic overload-induced left ventricular hypertrophy and dysfunction. Nucleosides Nucleotides Nucleic Acids 29:306-313.
83. Yin W, Zhang P, Huang JH, Zhang QY, Fan R, Li J, Zhou JJ, Hu YZ, Guo HT, Zhang SM, Wang YM, Kaye AD, Gu CH, Liu JC, Cheng L, Cui Q, Yi DH, Pei JM. 2009. Stimulation of kappa-opioid receptor reduces isoprenaline-induced cardiac hypertrophy and fibrosis. Eur J Pharmacol 607:135-142.
84. Yu CM, Lin H, Yang H, Kong SL, Zhang Q, Lee SW. 2002. Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation 105:1195-1201. (Pubitemid 34225820)
85. Zelarayan L, Renger A, Noack C, Zafiriou MP, Gehrke C, van derNagel R, Dietz R, de Windt L, Bergmann MW. 2009. NF-?B activation is required for adaptive cardiac hypertrophy. Cardiovasc Res 84:416-424.
86. Zhang S, Weinheimer C, Courtois M, Kovacs A, Zhang CE, Cheng AM, Wang Y, Muslin AJ. 2003. The role of the Grβ2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest 111:833-841. (Pubitemid 37074958)
87. Zorov DB, Juhaszova M, Yaniv Y, Nuss HB, Wang S, Sollott SJ. 2009. Regulation and pharmacology of the mitochondrial permeability transition pore. Cardiovasc Res 83:213-225.
88. Zuo YM, Wang XH, Gao S, Zhang Y. 2011. Oligomerized grape seed proanthocyanidins ameliorates isoproterenol-induced cardiac remodeling in rats: role of oxidative stress. Phytother Res 25:732-739.